We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Long-Term Follow-Up after High-Activity <sup>125</sup>I Brachytherapy for Pediatric Brain Tumors.
- Authors
Sneed, Penny K.; Russo, Carolyn; Scharfen, Cindy O.; Prados, Michael D.; Malec, Mary K.; Larson, David A.; Lamborn, Kathleen R.; Lamb, Sharon A.; Voss, Brigid; Weaver, Keith A.; Phillips, Theodore L.; Gutin, Philip H.; Wara, William M.; Edwards, Michael S.B.
- Abstract
A retrospective review including long-term follow-up (4.6-12.0 years) was performed of all 28 pediatric patients who underwent high-activity 125I brachytherapy at the University of California, San Francisco, for primary or recurrent brain tumors from 1980 until 1991. There were 4 glioblastomas, 11 high-grade nonglioblastoma multiforme (NGM) malignant gliomas, 10 contrast-enhancing low-grade NGM, 2 choroid plexus carcinomas, and 1 rhabdomyosarcoma. The 13 survivors included 7 of 8 patients with primary high-grade NGM, 2 of 3 patients with primary low-grade NGM, and 3 of 7 patients with recurrent low-grade NGM. Necrosis (with or without tumor) was identified in 17 of 22 reoperated patients. The mean Karnofsky performance status was 88 ± 9 at the time of brachytherapy, 87 ± 7 at 3 years, and 87 ± 9 in 11 patients alive at 6-12 years. Brachytherapy is a useful modality for treating selected pediatric brain tumors, and although focal necrosis is a common sequela, it does not tend to have a major impact on the Karnofsky performance status, if the implant site is amenable to reoperation. Copyright © 1996 S. Karger AG, Basel
- Publication
Pediatric Neurosurgery, 1996, Vol 24, Issue 6, p314
- ISSN
1016-2291
- Publication type
Article
- DOI
10.1159/000121061